Complete AI Training
Start for Free

Your job's AI kit

Get your AI kit

Tell us who you are and what you do. We show you your kit right away and email you the link: skills, prompts, AI agents, MCP servers and courses for your job.

500+ jobs ready, and we make a kit for any other job. No payment needed to look.

Share

AI news ·

South Korea to fast-track AI medical products in 2026 with custom approvals, data-based trials, and national certification

South Korea will launch a 2026 program to speed AI medical products with clearer approvals, standards, and export certification. Teams, prep data, trials, and MLOps now.

South Korea sets 2026 support program for AI-driven medical products: What product teams should do now

South Korea's Ministry of Food and Drug Safety (MFDS) plans to launch a 2026 program to speed the development, use, and export of medical products that apply AI. The ministry's annual policy report points to new approval routes, clear review standards, and a certification system built around performance and reliability.

The signal is simple: if you build digital health, AI SaMD, or AI-enabled drug development tools, Korea is preparing a faster, clearer path - with higher expectations on data quality and evidence.

Highlights from the ministry's plan

  • Lay the groundwork to expand AI-based medical product development and use.
  • Create a custom approval pathway for digital medical products.
  • Streamline rules for new-technology and "convergence-type" products (e.g., software + device, drug-device-software combos).
  • Define approval and review standards for digital information processing in AI-driven drug development.
  • Offer regulatory support to speed market entry, including data-based clinical trials and oversight of AI training data quality.
  • Develop national performance standards for AI-based digital medical and health-support devices, plus a certification system to back exports.

Why this matters for product development teams

This isn't just a policy change; it's a product constraint set. Your model choices, data pipelines, and clinical design will need to meet explicit standards and pass certification that buyers and regulators can trust.

  • Regulatory strategy: plan for a defined Korea-specific path for digital/AI products that may differ from the US/EU.
  • Evidence design: expect demand for data-driven trials and thorough dataset documentation (provenance, curation, bias checks).
  • MLOps maturity: reproducible training, clear versioning, and change control will be essential, especially for models that update.
  • Export leverage: certification could become a procurement shortcut with hospitals and distributors across Asia and beyond.

Action checklist for 2025 (to hit the 2026 window)

  • Map your product to a likely category (AI SaMD, clinical decision support, health-support device, AI for drug R&D) and define the evidence plan.
  • Audit your data supply chain: sources, consent, lineage, preprocessing, labeling QA, and subgroup performance reporting.
  • Document model behavior end to end: training config, versioning, datasets, monitoring, post-market update policy, rollback triggers.
  • Design data-based trial protocols now: endpoints, comparators, dataset representativeness for Korean populations, and external validation.
  • Stress-test against performance standards: accuracy, specificity/sensitivity, fairness metrics, clinical risk thresholds, and usability.
  • Prepare for certification: product file, test reports, cyber/privacy posture, real-world performance plan, and supplier attestations.
  • For convergence products, align device, software, and (if applicable) drug teams under a single change-control and evidence strategy.

If you need a global reference point for AI medical devices, see the FDA's AI/ML SaMD resources for principles that often echo across markets: FDA: AI/ML-enabled medical devices.

Certification and export: plan your proof

The ministry plans national performance standards and a certification system to back "high-reliability, high-quality" products. Treat this like a go-to-market asset you can reuse across sales, procurement, and partner integrations.

  • Build a clean, shareable performance dossier: datasets, test methods, limits, known failure modes, and human factors results.
  • Line up third-party testing where possible to speed certification.
  • Map certification outputs to EU MDR, US expectations, and IMDRF principles to reduce duplicate work.

Open questions to clarify with regulators

  • How will "learning" or periodically updated models be handled (change control, re-approval triggers)?
  • What qualifies as acceptable external validation for Korea-based use?
  • Will synthetic data be accepted, and under what constraints?
  • How will performance standards address subgroup performance and bias?
  • For convergence products, which component drives classification and evidence depth?

Timeline

  • 2025: Plan and align - data governance, clinical protocols, documentation, and internal audits.
  • 2026: Program rollout - expect formal standards, approval routes, and a certification track to come online.

Want to upskill your team on AI product workflows and evidence fundamentals ahead of 2026? Explore role-based programs here: Complete AI Training - Courses by job.

Share